Itaca App vs. Usual Care for Medication Adherence in Older Adults on Polypharmacy
Monitoring Medication Adherence in Patients Aged ≥65 Years on Polypharmacy: A Randomized Clinical Trial of the Itaca Mobile App vs. Usual Care
The goal of this clinical trial is to learn if the use of a mobile app called Itaca improves medication adherence in older adults (aged ≥65) in a home care setting. It will also assess the impact of the app on patient engagement, patient activation, quality of life, and the app's usability in the intervention group. The main question it aims to answer is:
- Does the use of the Itaca mobile application improve medication adherence among older adults in the home care setting compared with usual care?
- Does the use of the Itaca mobile application improve patient engagement, patient activation, and quality of life among older adults in the home care setting compared with usual care?
Researchers will compare usual care to see if the intervention using the Itaca mobile app is more effective in improving medication adherence.
Participants will:
- In the intervention group, use the Itaca app for 3 months
- In the intervention group, receive monthly phone calls to support adherence to the study protocol, monitor app use, and address any barriers
- In the intervention group, complete the usability scale at the end of the 3-month intervention period
- In both the intervention and control groups, complete the questionnaires at enrollment and after 3 months, at the end of the intervention period
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Lazio
-
Rome, Lazio, Italia, 00100
- Local Health Unit
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Age ≥ 65 years with chronic condition
- Taking three or more medications regardless of route of administration
- Able to understand and speak Italian and to adhere to the study by signing written informed
- Able to understand and speak Italian and to adhere to the study by signing written informed
Exclusion Criteria:
- Pediatric or adult (< 65 years)
- Taking fewer than three medications
- With diagnosed cognitive impairment or psychiatric disorder that could interfere with participation in the study
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Cuidados de apoyo
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Intervention group: Itaca app mobile
|
At baseline (T0), the research team will support participants in installing the ITACA application on their personal smartphone. An individual training session will be provided at T0. Medication reminder notifications will be activated according to each patient's prescribed regimen. The application will be used throughout the entire 3-month follow-up period. Researchers will contact participants by telephone at monthly intervals to monitor app use and address barriers. No formal assessments are performed at these contacts. At 3 months (T1), participants will complete the System Usability Scale (SUS) (subject to prior authorization and/or licensing for use) to evaluate perceived app usability. |
|
Comparador activo: Control group: Usual Care
|
At baseline (T0), participants will receive and be provided with an explanation of a written medication plan containing prescribed therapies, dosages, and administration schedules. Participants will continue standard clinical follow-up with their GP throughout the 3-month period. No digital tools or additional interventions will be provided beyond routine clinical practice. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Medication Adherence Score Levels
Periodo de tiempo: From enrollment to end of treatment at 3 months
|
Primary outcome is the change in adherence level measured by the Morisky Medication Adherence Scale (MMAS-4), subject to prior authorization and/or licensing for use.
|
From enrollment to end of treatment at 3 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Patient Health Engagement Score Levels
Periodo de tiempo: From enrollment to 3 months
|
Change in patient health engagement score measured by the PHE-s, subject to prior authorization and/or licensing for use.
|
From enrollment to 3 months
|
|
Change in Health-Related Quality of Life Score Levels
Periodo de tiempo: From enrollment to 3 months
|
Change in health-related quality of life score measured by the SF-12, subject to prior authorization and/or licensing for use.
|
From enrollment to 3 months
|
|
App Usability Score Levels
Periodo de tiempo: At the end of the intervention period, with a duration of 3 months
|
Usability measured by the System Usability Scale (SUS), subject to prior authorization and/or licensing for use, assessed only in the intervention group
|
At the end of the intervention period, with a duration of 3 months
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 7889 (CTEP)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Usual Care Group
-
Aarogyam UKNMP Medical Research Institute; Croydon Ayurveda Centre; Active Naturals Limited; AVP Research FoundationActivo, no reclutandoDesorden psiquiátricoIndia
-
University of Illinois at ChicagoFogarty International Center of the National Institute of HealthTerminadoCáncer de cuello uterino | ComportamientoEstados Unidos, Senegal
-
University of Texas at AustinTerminadoEsclerosis múltipleEstados Unidos
-
Icahn School of Medicine at Mount SinaiUniversity of WashingtonTerminadoCáncer colonrectal | Cáncer de vejigaEstados Unidos
-
NYU Langone HealthNational Institute on Aging (NIA)TerminadoDemenciaEstados Unidos
-
Assistance Publique Hopitaux De MarseilleReclutamiento
-
The University of Texas Health Science Center,...Tufts University; American Heart Association; Michael and Susan Dell FoundationReclutamientoNutrición en el embarazo de alto riesgoEstados Unidos
-
Saglik Bilimleri UniversitesiAún no reclutandoEfecto de la reflexología en los síntomas del síndrome premenstrual
-
University of LisbonAssociacao Protectora dos Diabeticos de PortugalTerminado
-
Silke Wiegand-Grefe, Prof. Dr.Charite University, Berlin, Germany; Hannover Medical School; University Hospital... y otros colaboradoresActivo, no reclutandoEnfermedades rarasAlemania